Erbitux and Asphyxia - a phase IV clinical study of FDA data

Summary:

Asphyxia is reported as a side effect among people who take Erbitux (cetuximab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Amlodipine, and have High blood pressure.

The phase IV clinical study analyzes which people have Asphyxia when taking Erbitux. It is created by eHealthMe based on reports of 19,227 people who have side effects when taking Erbitux from the FDA, and is updated regularly.

What is Erbitux?

Erbitux has active ingredients of cetuximab. It is often used in cancer. eHealthMe is studying from 19,276 Erbitux users. Check the latest studies of Erbitux.

What is Asphyxia?

Asphyxia (a condition in which there is an extreme decrease in the concentration of oxygen in the body) is found to be associated with 551 drugs and 821 conditions by eHealthMe. Check the latest studies of Asphyxia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

19,227 people reported to have side effects when taking Erbitux.
Among them, 22 people (0.11%) have Asphyxia.

Among these 22 people:

How long have people been on Erbitux when they have Asphyxia? *

What is the gender of people who have Asphyxia when taking Erbitux? *

female: 17.65 %
male: 82.35 %

What is the age of people who have Asphyxia when taking Erbitux? *

What are other drugs people take besides Erbitux? *

What are other side effects people have besides Asphyxia? *

Dyspnea (difficult or laboured breathing): 7 people, 31.82%
Loss Of Consciousness: 7 people, 31.82%
Hypotension (abnormally low blood pressure): 5 people, 22.73%
Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi): 4 people, 18.18%
Rashes (redness): 4 people, 18.18%
Itching: 4 people, 18.18%
Skin Blushing/flushing (a sudden reddening of the face, neck): 3 people, 13.64%
Arrhythmias (irregular heartbeat): 3 people, 13.64%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 13.64%
Blood Urea Increased: 2 people, 9.09%

What are the existing conditions these people have? *

High Blood Pressure: 4 people, 18.18%
Cancer - Throat Or Larynx: 3 people, 13.64%
Salivary Gland Cancer Recurrent (reoccurs salivary gland cancer): 2 people, 9.09%
Pneumonia: 2 people, 9.09%
Lip And/or Oral Cavity Cancer (cancer of lip or mouth): 2 people, 9.09%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 2 people, 9.09%
Colon Cancer Metastatic (cancer of colon spreads to other part of body): 2 people, 9.09%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 9.09%
Rectal Cancer (cancer of rectum): 1 person, 4.55%
Neoplasm Malignant (cancer tumour): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Erbitux and have Asphyxia?

- Check whether Asphyxia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Erbitux:

Erbitux (19,276 reports)

Asphyxia treatments and more:

Asphyxia (9,188 reports)

Browse all side effects of Erbitux:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Asphyxia:

Asphyxia (551 drugs)

Browse all the conditions that are associated with Asphyxia:

Asphyxia (821 conditions)

Related publications that referenced our studies

Gupta D, Shukla P, Bisht SS, Bhatt ML, Pant MC, Srivastava K, "Deep vein and artery thrombosis associated with cetuximab-based chemoradiotherapy", Indian journal of pharmacology, 2011 Jan .
Gupta D, Shukla P, Bisht SS, Bhatt ML, Pant MC, Srivastava K, "Deep vein and artery thrombosis associated with cetuximab-based chemoradiotherapy", Indian journal of pharmacology, 2011 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cetuximab (the active ingredients of Erbitux) and Erbitux (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.